Skip to content 
Search

Latest Stories

AstraZeneca to take profit from Covid vaccine sales

BRITISH pharmaceutical giant AstraZeneca said Friday (12) it has begun to sell its Covid vaccine at a profit as the company posted a third-quarter loss on higher costs.

AstraZeneca, which has sold its vaccine at cost during the pandemic in contrast to rivals including US giant Pfizer, said it expects "to progressively transition... to modest profitability as new orders are received" in the current fourth quarter and beyond.


AstraZeneca posted a net loss of $1.65 billion for the third quarter compared with a profit after tax of around $650 million in the July-September period last year, a statement said.

AstraZeneca said it experienced higher costs in the current third quarter following its $39bn takeover of US biotech company Alexion, as well as increased research and development expenses across multiple programmes, including its Covid treatments. The group completed the Alexion takeover earlier this year.

Last month, the drugs company revealed positive results from a trial of a treatment for Covid-19 symptoms, which is being produced alongside its vaccine.

Made from a combination of two antibodies, the AZD7442 treatment had been undergoing final clinical trials to assess its safety and efficacy.

AstraZeneca said the limited profit contribution from the Covid vaccine in the current fourth quarter "is expected to offset costs relating to" AZD7442.

Chief executive Pascal Soriot told reporters that AstraZeneca had always planned to stop selling its Covid vaccine at cost.

But he stressed that the company wants "the vaccine to remain affordable".

The group added that revenue from its Covid vaccine, developed with the University of Oxford, totalled $2.22bn in the year to date following delivery of around 580 million doses worldwide.

Soriot said the company had "saved millions of hospitalisations" thanks to being the world's second-largest provider of Covid vaccines after Pfizer.

The drugs giant said total group revenue soared 50 per cent in the third quarter to almost $9.9 billion.

"AstraZeneca's scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery... including our long-acting antibody combination showing promise in both prevention and treatment of Covid-19," Soriot said in the earnings statement.

Since taking the helm at AstraZeneca in 2012, Soriot has pushed the company into lucrative treatments such as cancer therapies, and the Alexion takeover gives it more heft in areas such as treating blood disorders.

More For You

Bangladesh seeks US deal to shield garment industry from tariffs

Workers are engaged at their sewing stations in a garment factory in Savar, on the outskirts of Dhaka, on April 9, 2025. (Photo by MUNIR UZ ZAMAN/AFP via Getty Images)

Bangladesh seeks US deal to shield garment industry from tariffs

BANGLADESH, the world's second-biggest garment manufacturer, aims to strike a trade deal with the US before Donald Trump's punishing tariffs kick in next week, said the country's top commerce official.

Dhaka is proposing to buy Boeing planes and boost imports of US wheat, cotton and oil in a bid to reduce the trade deficit, which Trump used as the reason for imposing painful levies in his "Liberation Day" announcement.

Keep ReadingShow less
UK business district
The Canary Wharf business district including global financial institutions in London.
Getty Images

Bond yields ease following Starmer’s support for Reeves

THE COST of UK government borrowing fell on Thursday, partially reversing the rise seen after Chancellor Rachel Reeves became emotional during Prime Minister’s Questions.

The yield on 10-year government bonds dropped to 4.55 per cent, down from 4.61 per cent the previous day. The pound also recovered slightly to $1.3668 (around £1.00), though it did not regain all its earlier losses.

Keep ReadingShow less
modi-trump-getty
Modi shakes hands with Trump before a meeting at Hyderabad House in New Delhi on February 25, 2020. (Photo: Getty Images)
Getty Images

Indian exporters watch closely as Trump says trade deal with India likely

THE US could reach a trade deal with India that would help American companies compete more easily in the Indian market and reduce tariff rates, President Donald Trump said on Tuesday. However, he cast doubt on a similar deal with Japan.

Speaking to reporters on Air Force One, Trump said he believed India was ready to lower trade barriers, potentially paving the way for an agreement that would avoid the 26 per cent tariff rate he had announced on April 2 and paused until July 9.

Keep ReadingShow less
Kolhapuri sandal sales surge in India post Prada controversy

Customers shop for 'Kolhapuri' sandals, an Indian ethnic footwear, at a store in New Delhi, India, June 27, 2025. REUTERS/Adnan Abidi

Kolhapuri sandal sales surge in India post Prada controversy

INDIAN footwear sellers and artisans are tapping into nationalist pride stoked by the Prada 'sandal scandal' in a bid to boost sales of ethnic slippers with history dating back to the 12th century, raising hopes of reviving a struggling craft.

Sales are surging over the past week for the 'Kolhapuri' sandals that have garnered global attention after Prada sparked a controversy by showcasing similar designs in Milan, without initially crediting the footwear's origins.

Keep ReadingShow less
UK business district
The Canary Wharf business district including global financial institutions in London.
Getty Images

Economy grew 0.7 per cent in Q1 2025, fastest in a year

THE UK economy expanded at its fastest pace in a year during the first quarter of 2025, driven by a rise in home purchases ahead of a tax deadline and higher manufacturing output before the introduction of new US import tariffs.

Gross domestic product rose by 0.7 per cent in the January-to-March period, the Office for National Statistics (ONS) said, confirming its earlier estimate. This was the strongest quarterly growth since the first quarter of 2024.

Keep ReadingShow less